{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:08:58Z","timestamp":1780441738687,"version":"3.54.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Open Project Program of Hubei Key Laboratory","award":["2025KFH001"],"award-info":[{"award-number":["2025KFH001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-08091-0","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T08:55:59Z","timestamp":1776502559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-pharmacological interventions for antipsychotic drug-related metabolic abnormalities: a systematic narrative review"],"prefix":"10.1186","volume":"26","author":[{"given":"Jingfang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinna","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"8091_CR1","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KGMM Alberti","year":"2009","unstructured":"Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120:1640\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192644.","journal-title":"Circulation"},{"key":"8091_CR2","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an american heart association\/national heart, lung, and blood institute scientific statement. Circulation. 2005;112:2735\u201352. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.169404.","journal-title":"Circulation"},{"key":"8091_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/nrendo.2011.72","volume":"7","author":"BW Smith","year":"2011","unstructured":"Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011;7:456\u201365. https:\/\/doi.org\/10.1038\/nrendo.2011.72.","journal-title":"Nat Rev Endocrinol"},{"key":"8091_CR4","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.2337\/dc12-0336","volume":"35","author":"K Esposito","year":"2012","unstructured":"Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35:2402\u201311. https:\/\/doi.org\/10.2337\/dc12-0336.","journal-title":"Diabetes Care"},{"key":"8091_CR5","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","volume":"56","author":"S Mottillo","year":"2010","unstructured":"Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.034.","journal-title":"J Am Coll Cardiol"},{"key":"8091_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12889-017-4041-1","volume":"17","author":"P Ranasinghe","year":"2017","unstructured":"Ranasinghe P, Mathangasinghe Y, Jayawardena R, Hills AP, Misra A. Prevalence and trends of metabolic syndrome among adults in the Asia-pacific region: a systematic review. BMC Public Health. 2017;17:101. https:\/\/doi.org\/10.1186\/s12889-017-4041-1.","journal-title":"BMC Public Health"},{"key":"8091_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1210\/er.2008-0024","volume":"29","author":"M-A Cornier","year":"2008","unstructured":"Cornier M-A, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev. 2008;29:777\u2013822. https:\/\/doi.org\/10.1210\/er.2008-0024.","journal-title":"Endocr Rev"},{"key":"8091_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0168-8227(03)00066-4","volume":"61","author":"F Azizi","year":"2003","unstructured":"Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: tehran lipid and glucose study. Diabetes Res Clin Pr. 2003;61:29\u201337. https:\/\/doi.org\/10.1016\/s0168-8227(03)00066-4.","journal-title":"Diabetes Res Clin Pr"},{"key":"8091_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijcard.2018.01.139","volume":"259","author":"D Shin","year":"2018","unstructured":"Shin D, Kongpakpaisarn K, Bohra C. Trends in the prevalence of metabolic syndrome and its components in the United States 2007\u20132014. Int J Cardiol. 2018;259:216\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2018.01.139.","journal-title":"Int J Cardiol"},{"key":"8091_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.5551\/jat.13.202","volume":"13","author":"H Arai","year":"2006","unstructured":"Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, et al. Prevalence of metabolic syndrome in the general japanese population in 2000. J Atheroscler Thromb. 2006;13:202\u20138. https:\/\/doi.org\/10.5551\/jat.13.202.","journal-title":"J Atheroscler Thromb"},{"key":"8091_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/met.2008.0055","volume":"7","author":"MZI Hydrie","year":"2009","unstructured":"Hydrie MZI, Shera AS, Fawwad A, Basit A, Hussain A. Prevalence of metabolic syndrome in urban pakistan (karachi): comparison of newly proposed international diabetes federation and modified adult treatment panel III criteria. Metab Syndr Relat D. 2009;7:119\u201324. https:\/\/doi.org\/10.1089\/met.2008.0055.","journal-title":"Metab Syndr Relat D"},{"key":"8091_CR12","doi-asserted-by":"publisher","unstructured":"Maaroganye K, Mohapi M, Kr\u00fcger C, Rheeder P. The prevalence of metabolic syndrome and its associated factors in long-term patients in a specialist psychiatric hospital in South Africa. Afr J Psychiatry. 2013;16. https:\/\/doi.org\/10.4314\/ajpsy.v16i6.53.","DOI":"10.4314\/ajpsy.v16i6.53"},{"key":"8091_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/wps.20309","volume":"15","author":"D Vancampfort","year":"2016","unstructured":"Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World psychiatry: off j World Psychiatr Assoc (WPA). 2016;15:166\u201374. https:\/\/doi.org\/10.1002\/wps.20309.","journal-title":"World psychiatry: off j World Psychiatr Assoc (WPA)"},{"key":"8091_CR14","doi-asserted-by":"publisher","unstructured":"Kar N, Barreto S. Influence of lifestyle factors on metabolic syndrome in psychiatric patients attending a community mental health setting: a cross-sectional study. Indian J Psychol Med. 2024;46:313\u201322. https:\/\/doi.org\/10.1177\/02537176231219770.","DOI":"10.1177\/02537176231219770"},{"key":"8091_CR15","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1177\/0269881109102788","volume":"24","author":"RIG Holt","year":"2010","unstructured":"Holt RIG, Abdelrahman T, Hirsch M, Dhesi Z, George T, Blincoe T, et al. The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. J Psychopharmacol (Oxf Engl). 2010;24:867\u201373. https:\/\/doi.org\/10.1177\/0269881109102788.","journal-title":"J Psychopharmacol (Oxf Engl)"},{"key":"8091_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1399-5618.2007.00520.x","volume":"10","author":"R van Winkel","year":"2008","unstructured":"van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord. 2008;10:342\u20138. https:\/\/doi.org\/10.1111\/j.1399-5618.2007.00520.x.","journal-title":"Bipolar Disord"},{"key":"8091_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1176\/appi.psy.47.6.491","volume":"47","author":"RA Bermudes","year":"2006","unstructured":"Bermudes RA, Keck PE, Welge JA. The prevalence of the metabolic syndrome in psychiatric inpatients with primary psychotic and mood disorders. Psychosomatics. 2006;47:491\u20137. https:\/\/doi.org\/10.1176\/appi.psy.47.6.491.","journal-title":"Psychosomatics"},{"key":"8091_CR18","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.psychres.2012.03.043","volume":"200","author":"S Grover","year":"2012","unstructured":"Grover S, Aggarwal M, Dutt A, Chakrabarti S, Avasthi A, Kulhara P, et al. Prevalence of metabolic syndrome in patients with schizophrenia in India. Psychiat Res. 2012;200:1035\u20137. https:\/\/doi.org\/10.1016\/j.psychres.2012.03.043.","journal-title":"Psychiat Res"},{"key":"8091_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/wps.20252","volume":"14","author":"D Vancampfort","year":"2015","unstructured":"Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World psychiatry: off j World Psychiatr Assoc (WPA). 2015;14:339\u201347. https:\/\/doi.org\/10.1002\/wps.20252.","journal-title":"World psychiatry: off j World Psychiatr Assoc (WPA)"},{"key":"8091_CR20","doi-asserted-by":"publisher","first-page":"625935","DOI":"10.3389\/fpsyt.2021.625935","volume":"12","author":"MH Sneller","year":"2021","unstructured":"Sneller MH, de Boer N, Everaars S, Schuurmans M, Guloksuz S, Cahn W, et al. Clinical, biochemical and genetic variables associated with metabolic syndrome in patients with schizophrenia spectrum disorders using second-generation antipsychotics: a systematic review. Front Psychiatry. 2021;12:625935. https:\/\/doi.org\/10.3389\/fpsyt.2021.625935.","journal-title":"Front Psychiatry"},{"key":"8091_CR21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1017\/S1461145712001277","volume":"16 6","author":"J Zhang","year":"2013","unstructured":"Zhang J, Gallego J, Robinson D, Malhotra A, Kane J, Correll C. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16 6:1205\u201318. https:\/\/doi.org\/10.1017\/S1461145712001277.","journal-title":"Int J Neuropsychopharmacol"},{"key":"8091_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64\u201377. https:\/\/doi.org\/10.1016\/S2215-0366(19)30416-X.","journal-title":"Lancet Psychiatry"},{"key":"8091_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M De Hert","year":"2011","unstructured":"De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8:114\u201326. https:\/\/doi.org\/10.1038\/nrendo.2011.156.","journal-title":"Nat Rev Endocrinol"},{"key":"8091_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/pharmacy11010023","volume":"11","author":"K Hurley","year":"2023","unstructured":"Hurley K, O\u2019Brien S, Halleran C, Byrne D, Foley E, Cunningham J, et al. Metabolic syndrome in adults receiving clozapine; the need for pharmacist support. Pharm (Basel Switz). 2023;11:23. https:\/\/doi.org\/10.3390\/pharmacy11010023.","journal-title":"Pharm (Basel Switz)"},{"key":"8091_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/AMH.AMH_4_20","volume":"21","author":"D Panati","year":"2020","unstructured":"Panati D, Sudhakar T, Swetha P, Sayeli V. A comparative study on metabolic syndrome in patients with schizophrenia treated using first-generation and second-generation antipsychotics. Arch Ment Health. 2020;21:4\u201311. https:\/\/doi.org\/10.4103\/AMH.AMH_4_20.","journal-title":"Arch Ment Health"},{"key":"8091_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.schres.2008.01.028","volume":"101","author":"M Hert","year":"2008","unstructured":"Hert M, Schreurs V, Sweers K, Eyck D, Hanssens L, \u0160inko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101:295\u2013303. https:\/\/doi.org\/10.1016\/j.schres.2008.01.028.","journal-title":"Schizophr Res"},{"key":"8091_CR27","doi-asserted-by":"publisher","unstructured":"Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World psychiatry: off j World Psychiatr Assoc (WPA). 2017;16:163\u201380. https:\/\/doi.org\/10.1002\/wps.20420.","DOI":"10.1002\/wps.20420"},{"key":"8091_CR28","doi-asserted-by":"publisher","first-page":"e60970","DOI":"10.7554\/eLife.60970","volume":"9","author":"S Ninagawa","year":"2020","unstructured":"Ninagawa S, Tada S, Okumura M, Inoguchi K, Kinoshita M, Kanemura S, et al. Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes. eLife. 2020;9:e60970. https:\/\/doi.org\/10.7554\/eLife.60970.","journal-title":"eLife"},{"key":"8091_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.schres.2020.12.005","volume":"228","author":"C Kowalchuk","year":"2021","unstructured":"Kowalchuk C, Castellani L, Kanagsundaram P, McIntyre WB, Asgariroozbehani R, Giacca A, et al. Olanzapine-induced insulin resistance may occur via attenuation of central KATP channel-activation. Schizophr Res. 2021;228:112\u20137. https:\/\/doi.org\/10.1016\/j.schres.2020.12.005.","journal-title":"Schizophr Res"},{"key":"8091_CR30","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1177\/02698811211026456","volume":"35","author":"GP Reynolds","year":"2021","unstructured":"Reynolds GP. High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines? J Psychopharmacol (Oxf Engl). 2021;35:1030\u20136. https:\/\/doi.org\/10.1177\/02698811211026456.","journal-title":"J Psychopharmacol (Oxf Engl)"},{"key":"8091_CR31","doi-asserted-by":"publisher","first-page":"e0277211","DOI":"10.1371\/journal.pone.0277211","volume":"17","author":"N Stogios","year":"2022","unstructured":"Stogios N, Hamel L, Smith E, Sanches M, Remington G, Voineskos A, et al. Investigating the effects of antipsychotics on brain insulin action: study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls. PLoS ONE. 2022;17:e0277211. https:\/\/doi.org\/10.1371\/journal.pone.0277211.","journal-title":"PLoS ONE"},{"key":"8091_CR32","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/molecules26072101","volume":"26","author":"S Jayaraman","year":"2021","unstructured":"Jayaraman S, Devarajan N, Rajagopal P, Babu S, Ganesan SK, Veeraraghavan VP, et al. \u03b2-sitosterol circumvents obesity induced inflammation and insulin resistance by down-regulating IKK\u03b2\/NF-\u03baB and JNK signaling pathway in adipocytes of type 2 diabetic rats. Mol (Basel Switz). 2021;26:2101. https:\/\/doi.org\/10.3390\/molecules26072101.","journal-title":"Mol (Basel Switz)"},{"key":"8091_CR33","doi-asserted-by":"publisher","first-page":"112071","DOI":"10.1016\/j.biopha.2021.112071","volume":"142","author":"H Li","year":"2021","unstructured":"Li H, Wang C, Zhao J, Guo C. JNK downregulation improves olanzapine-induced insulin resistance by suppressing IRS1Ser307 phosphorylation and reducing inflammation. Biomed Pharmacother = Biomed Pharmacother. 2021;142:112071. https:\/\/doi.org\/10.1016\/j.biopha.2021.112071.","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"key":"8091_CR34","doi-asserted-by":"publisher","first-page":"1097284","DOI":"10.3389\/fphar.2023.1097284","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen H, Cao T, Zhang B, Cai H. The regulatory effects of second-generation antipsychotics on lipid metabolism: potential mechanisms mediated by the gut microbiota and therapeutic implications. Front Pharmacol. 2023;14:1097284. https:\/\/doi.org\/10.3389\/fphar.2023.1097284.","journal-title":"Front Pharmacol"},{"key":"8091_CR35","doi-asserted-by":"publisher","first-page":"104703","DOI":"10.1016\/j.phrs.2020.104703","volume":"155","author":"Y Su","year":"2020","unstructured":"Su Y, Liu X, Lian J, Deng C. Epigenetic histone modulations of PPAR\u03b3 and related pathways contribute to olanzapine-induced metabolic disorders. Pharmacol Res. 2020;155:104703. https:\/\/doi.org\/10.1016\/j.phrs.2020.104703.","journal-title":"Pharmacol Res"},{"key":"8091_CR36","doi-asserted-by":"publisher","first-page":"110097","DOI":"10.1016\/j.pnpbp.2020.110097","volume":"106","author":"C Zeng","year":"2021","unstructured":"Zeng C, Yang P, Cao T, Gu Y, Li N, Zhang B, et al. Gut microbiota: an intermediary between metabolic syndrome and cognitive deficits in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2021;106:110097. https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110097.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"8091_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/cells11010110","volume":"11","author":"C Duarte-Hospital","year":"2021","unstructured":"Duarte-Hospital C, T\u00eate A, Brial F, Benoit L, Koual M, Tomkiewicz C, et al. Mitochondrial dysfunction as a hallmark of environmental injury. Cells. 2021;11:110. https:\/\/doi.org\/10.3390\/cells11010110.","journal-title":"Cells"},{"key":"8091_CR38","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.3390\/biomedicines10123239","volume":"10","author":"SK Wong","year":"2022","unstructured":"Wong SK, Ramli FF, Ali A, Ibrahim N, \u2019Izzah. Genetics of cholesterol-related genes in metabolic syndrome: a review of current evidence. Biomedicines. 2022;10:3239. https:\/\/doi.org\/10.3390\/biomedicines10123239.","journal-title":"Biomedicines"},{"key":"8091_CR39","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","volume":"40 6","author":"Y Mizuno","year":"2014","unstructured":"Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker W, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophrenia Bull. 2014;40 6:1385\u2013403. https:\/\/doi.org\/10.1093\/schbul\/sbu030.","journal-title":"Schizophrenia Bull"},{"key":"8091_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.5455\/medarh.2022.76.297-300","volume":"76","author":"F Rahman","year":"2022","unstructured":"Rahman F, Tuba S. Lactic acidosis associated with metformin in patients with diabetic kidney disease. Med Arch (Sarajevo Bosnia Herzeg). 2022;76:297\u2013300. https:\/\/doi.org\/10.5455\/medarh.2022.76.297-300.","journal-title":"Med Arch (Sarajevo Bosnia Herzeg)"},{"key":"8091_CR41","doi-asserted-by":"publisher","first-page":"e24220","DOI":"10.7759\/cureus.24220","volume":"14","author":"S Ashraf","year":"2022","unstructured":"Ashraf S, Upreti P, Karki S, Khan M, Nasr R. Metformin-associated lactic acidosis: a case report and review. Cureus. 2022;14:e24220. https:\/\/doi.org\/10.7759\/cureus.24220.","journal-title":"Cureus"},{"key":"8091_CR42","doi-asserted-by":"publisher","first-page":"104201","DOI":"10.1016\/j.phrs.2019.03.010","volume":"154","author":"J Bouitbir","year":"2020","unstructured":"Bouitbir J, Sanvee GM, Panajatovic MV, Singh F, Kr\u00e4henb\u00fchl S. Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacol Res. 2020;154:104201. https:\/\/doi.org\/10.1016\/j.phrs.2019.03.010.","journal-title":"Pharmacol Res"},{"key":"8091_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10557-020-07060-3","volume":"35","author":"Q Yu","year":"2021","unstructured":"Yu Q, Ma X, Wang Y, Shi H, An J, Wang Y, et al. Dietary cholesterol exacerbates statin-induced hepatic toxicity in syrian golden hamsters and in patients in an observational cohort study. Cardiovasc Drugs Ther. 2021;35:367\u201380. https:\/\/doi.org\/10.1007\/s10557-020-07060-3.","journal-title":"Cardiovasc Drugs Ther"},{"key":"8091_CR44","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487\u201397. https:\/\/doi.org\/10.1056\/NEJMra050100.","journal-title":"N Engl J Med"},{"key":"8091_CR45","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/2045125312474019","volume":"3","author":"K Higashi","year":"2013","unstructured":"Higashi K, Medic G, Littlewood KJ, Diez T, Granstr\u00f6m O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3:200\u201318. https:\/\/doi.org\/10.1177\/2045125312474019.","journal-title":"Ther Adv Psychopharmacol"},{"key":"8091_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fphar.2013.00091","volume":"4","author":"P Kardas","year":"2013","unstructured":"Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91. https:\/\/doi.org\/10.3389\/fphar.2013.00091.","journal-title":"Front Pharmacol"},{"key":"8091_CR47","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.20060","volume":"12","author":"JM Kane","year":"2013","unstructured":"Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World psychiatry: off j World Psychiatr Assoc (WPA). 2013;12:216\u201326. https:\/\/doi.org\/10.1002\/wps.20060.","journal-title":"World psychiatry: off j World Psychiatr Assoc (WPA)"},{"key":"8091_CR48","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.numecd.2020.02.020","volume":"30","author":"M Abbate","year":"2020","unstructured":"Abbate M, Gallardo-Alfaro L, Bibiloni MDM, Tur JA. Efficacy of dietary intervention or in combination with exercise on primary prevention of cardiovascular disease: a systematic review. Nutr metab cardiovasc dis: NMCD. 2020;30:1080\u201393. https:\/\/doi.org\/10.1016\/j.numecd.2020.02.020.","journal-title":"Nutr metab cardiovasc dis: NMCD"},{"key":"8091_CR49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/schbul\/sbv101","volume":"42","author":"EE McGinty","year":"2016","unstructured":"McGinty EE, Baller J, Azrin ST, Juliano-Bult D, Daumit GL. Interventions to address medical conditions and health-risk behaviors among persons with serious mental illness: a comprehensive review. Schizophrenia Bull. 2016;42:96\u2013124. https:\/\/doi.org\/10.1093\/schbul\/sbv101.","journal-title":"Schizophrenia Bull"},{"key":"8091_CR50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1192\/bjp.bp.117.199315","volume":"211","author":"A Looijmans","year":"2017","unstructured":"Looijmans A, Stiekema APM, Bruggeman R, van der Meer L, Stolk RP, Schoevers RA, et al. Changing the obesogenic environment to improve cardiometabolic health in residential patients with a severe mental illness: cluster randomised controlled trial. Br J Psychiatry. 2017;211:296\u2013303. https:\/\/doi.org\/10.1192\/bjp.bp.117.199315.","journal-title":"Br J Psychiatry"},{"key":"8091_CR51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.schres.2009.10.012","volume":"116","author":"M Alvarez-Jim\u00e9nez","year":"2010","unstructured":"Alvarez-Jim\u00e9nez M, Mart\u00ednez-Garc\u00eda O, P\u00e9rez-Iglesias R, Ram\u00edrez ML, V\u00e1zquez-Barquero JL, Crespo-Facorro B. Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr Res. 2010;116:16\u20139. https:\/\/doi.org\/10.1016\/j.schres.2009.10.012.","journal-title":"Schizophr Res"},{"key":"8091_CR52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1471-244X-13-60","volume":"13","author":"C Attux","year":"2013","unstructured":"Attux C, Martini LC, Elkis H, Tamai S, Freirias A, Camargo M, das GM, et al. A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia. BMC Psychiatry. 2013;13:60. https:\/\/doi.org\/10.1186\/1471-244X-13-60.","journal-title":"BMC Psychiatry"},{"key":"8091_CR53","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1176\/ps.62.7.pss6207_0800","volume":"62","author":"C Brown","year":"2011","unstructured":"Brown C, Goetz J, Hamera E. Weight loss intervention for people with serious mental illness: a randomized controlled trial of the RENEW program. Psychiatr Serv. 2011;62:800\u20132. https:\/\/doi.org\/10.1176\/ps.62.7.pss6207_0800.","journal-title":"Psychiatr Serv"},{"key":"8091_CR54","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3109\/15622975.2011.592546","volume":"15","author":"J Cordes","year":"2014","unstructured":"Cordes J, Th\u00fcnker J, Regenbrecht G, Zielasek J, Correll CU, Schmidt-Kraepelin C, et al. Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. World J Biol Psychiatry: Off J World Fed Soc Biol Psychiatry. 2014;15:229\u201341. https:\/\/doi.org\/10.3109\/15622975.2011.592546.","journal-title":"World J Biol Psychiatry: Off J World Fed Soc Biol Psychiatry"},{"issue":"Suppl 1","key":"8091_CR55","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11606-016-3960-3","volume":"32","author":"ZD Erickson","year":"2017","unstructured":"Erickson ZD, Kwan CL, Gelberg HA, Arnold IY, Chamberlin V, Rosen JA, et al. A randomized, controlled multisite study of behavioral interventions for veterans with mental illness and antipsychotic medication-associated obesity. J Gen Intern Med. 2017;32(Suppl 1):32\u20139. https:\/\/doi.org\/10.1007\/s11606-016-3960-3.","journal-title":"J Gen Intern Med"},{"key":"8091_CR56","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.4088\/JCP.14m09552","volume":"77","author":"ZD Erickson","year":"2016","unstructured":"Erickson ZD, Mena SJ, Pierre JM, Blum LH, Martin E, Hellemann GS, et al. Behavioral interventions for antipsychotic medication-associated obesity: a randomized, controlled clinical trial. J Clin Psychiat. 2016;77:e183\u2013189. https:\/\/doi.org\/10.4088\/JCP.14m09552.","journal-title":"J Clin Psychiat"},{"key":"8091_CR57","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.eurpsy.2015.09.006","volume":"30","author":"R Masa-Font","year":"2015","unstructured":"Masa-Font R, Fern\u00e1ndez-San-Mart\u00edn MI, Mart\u00edn L\u00f3pez LM, Alba Mu\u00f1oz AM, Oller Canet S, Mart\u00edn Royo J, et al. The effectiveness of a program of physical activity and diet to modify cardiovascular risk factors in patients with severe mental illness after 3-month follow-up: CAPiCOR randomized clinical trial. Eur Psychiatry. 2015;30:1028\u201336. https:\/\/doi.org\/10.1016\/j.eurpsy.2015.09.006.","journal-title":"Eur Psychiatry"},{"key":"8091_CR58","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1007\/s10597-014-9716-9","volume":"50","author":"CA Green","year":"2014","unstructured":"Green CA, Janoff SL, Yarborough BJH, Yarborough MT. A 12-week weight reduction intervention for overweight individuals taking antipsychotic medications. Community Ment Health J. 2014;50:974\u201380. https:\/\/doi.org\/10.1007\/s10597-014-9716-9.","journal-title":"Community Ment Health J"},{"key":"8091_CR59","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/oby.21205","volume":"23","author":"CA Green","year":"2015","unstructured":"Green CA, Yarborough BJH, Leo MC, Stumbo SP, Perrin NA, Nichols GA, et al. Weight maintenance following the STRIDE lifestyle intervention for individuals taking antipsychotic medications. Obes (Silver Spring). 2015;23:1995\u20132001. https:\/\/doi.org\/10.1002\/oby.21205.","journal-title":"Obes (Silver Spring)"},{"key":"8091_CR60","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1176\/appi.ajp.2014.14020173","volume":"172","author":"CA Green","year":"2015","unstructured":"Green CA, Yarborough BJH, Leo MC, Yarborough MT, Stumbo SP, Janoff SL, et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry. 2015;172:71\u201381. https:\/\/doi.org\/10.1176\/appi.ajp.2014.14020173.","journal-title":"Am J Psychiatry"},{"key":"8091_CR61","doi-asserted-by":"publisher","first-page":"e0185881","DOI":"10.1371\/journal.pone.0185881","volume":"12","author":"AS Jakobsen","year":"2017","unstructured":"Jakobsen AS, Speyer H, N\u00f8rgaard HCB, Karlsen M, Birk M, Hjorth\u00f8j C, et al. Effect of lifestyle coaching versus care coordination versus treatment as usual in people with severe mental illness and overweight: Two-years follow-up of the randomized CHANGE trial. PLoS ONE. 2017;12:e0185881. https:\/\/doi.org\/10.1371\/journal.pone.0185881.","journal-title":"PLoS ONE"},{"key":"8091_CR62","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4088\/JCP.13m08503","volume":"75","author":"K Lovell","year":"2014","unstructured":"Lovell K, Wearden A, Bradshaw T, Tomenson B, Pedley R, Davies LM, et al. An exploratory randomized controlled study of a healthy living intervention in early intervention services for psychosis: the INTERvention to encourage ACTivity, improve diet, and reduce weight gain (INTERACT) study. J Clin Psychiatry. 2014;75:498\u2013505. https:\/\/doi.org\/10.4088\/JCP.13m08503.","journal-title":"J Clin Psychiatry"},{"key":"8091_CR63","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/jan.12012","volume":"69","author":"K Usher","year":"2013","unstructured":"Usher K, Park T, Foster K, Buettner P. A randomized controlled trial undertaken to test a nurse-led weight management and exercise intervention designed for people with serious mental illness who take second generation antipsychotics. J Adv Nurs. 2013;69:1539\u201348. https:\/\/doi.org\/10.1111\/jan.12012.","journal-title":"J Adv Nurs"},{"key":"8091_CR64","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1176\/ps.2007.58.4.544","volume":"58","author":"M-K Wu","year":"2007","unstructured":"Wu M-K, Wang C-K, Bai Y-M, Huang C-Y, Lee S-D. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv (Wash DC). 2007;58:544\u201350. https:\/\/doi.org\/10.1176\/ps.2007.58.4.544.","journal-title":"Psychiatr Serv (Wash DC)"},{"key":"8091_CR65","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1176\/appi.ps.201400535","volume":"67","author":"BJH Yarborough","year":"2016","unstructured":"Yarborough BJH, Leo MC, Yarborough MT, Stumbo S, Janoff SL, Perrin NA, et al. Improvement in body image, perceived health, and health-related self-efficacy among people with serious mental illness: the STRIDE study. Psychiatr Serv. 2016;67:296\u2013301. https:\/\/doi.org\/10.1176\/appi.ps.201400535.","journal-title":"Psychiatr Serv"},{"key":"8091_CR66","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.schres.2023.09.036","volume":"261","author":"B Fern\u00e1ndez-Abascal","year":"2023","unstructured":"Fern\u00e1ndez-Abascal B, Su\u00e1rez-Pinilla M, Cobo-Corrales C, Crespo-Facorro B, Su\u00e1rez-Pinilla P. Lifestyle intervention based on exercise and behavioural counselling and its effect on physical and psychological health in outpatients with schizophrenia spectrum disorders. An exploratory, pragmatic randomized clinical trial. Schizophr Res. 2023;261:256\u201368. https:\/\/doi.org\/10.1016\/j.schres.2023.09.036.","journal-title":"Schizophr Res"},{"key":"8091_CR67","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF02850000","volume":"24","author":"W Milano","year":"2007","unstructured":"Milano W, Grillo F, Del Mastro A, De Rosa M, Sanseverino B, Petrella C, et al. Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study. Adv Ther. 2007;24:123\u201334. https:\/\/doi.org\/10.1007\/BF02850000.","journal-title":"Adv Ther"},{"key":"8091_CR68","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1186\/s12888-022-04426-9","volume":"22","author":"A Sevillano-Jim\u00e9nez","year":"2022","unstructured":"Sevillano-Jim\u00e9nez A, Romero-Salda\u00f1a M, Garc\u00eda-Mellado JA, Carrascal-Laso L, Garc\u00eda-Rodr\u00edguez M, Molina-Luque R, et al. Impact of high prebiotic and probiotic dietary education in the SARS-CoV-2 era: improved cardio-metabolic profile in schizophrenia spectrum disorders. BMC Psychiatry. 2022;22:781\u201393. https:\/\/doi.org\/10.1186\/s12888-022-04426-9.","journal-title":"BMC Psychiatry"},{"key":"8091_CR69","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1186\/s12888-024-06061-y","volume":"24","author":"P Basafa-Roodi","year":"2024","unstructured":"Basafa-Roodi P, Jazayeri S, Hadi F, Paghaleh SJ, Khosravi-darani K, Malakouti SK. Effects of synbiotic supplementation on the components of metabolic syndrome in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. BMC Psychiatry. 2024;24:669\u201379. https:\/\/doi.org\/10.1186\/s12888-024-06061-y.","journal-title":"BMC Psychiatry"},{"key":"8091_CR70","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.psychres.2017.12.028","volume":"261","author":"F Behdani","year":"2018","unstructured":"Behdani F, Roudbaraki SN, Saberi-Karimian M, Tayefi M, Hebrani P, Akhavanrezayat A, et al. Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate. Psychiat Res. 2018;261:243\u20137. https:\/\/doi.org\/10.1016\/j.psychres.2017.12.028.","journal-title":"Psychiat Res"},{"key":"8091_CR71","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/2008-2231-20-43","volume":"20","author":"T Faghihi","year":"2012","unstructured":"Faghihi T, Jahed A, Mahmoudi-Gharaei J, Sharifi V, Akhondzadeh S, Ghaeli P. Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial. Daru. 2012;20:43. https:\/\/doi.org\/10.1186\/2008-2231-20-43.","journal-title":"Daru"},{"key":"8091_CR72","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/schbul\/sbac044","volume":"48","author":"J Huang","year":"2022","unstructured":"Huang J, Kang D, Zhang F, Yang Y, Liu C, Xiao J, et al. Probiotics plus dietary fiber supplements attenuate olanzapine-induced weight gain in drug-na\u00efve first-episode schizophrenia patients: two randomized clinical trials. Schizophrenia Bull. 2022;48:850\u20139. https:\/\/doi.org\/10.1093\/schbul\/sbac044.","journal-title":"Schizophrenia Bull"},{"key":"8091_CR73","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.schres.2021.02.012","volume":"230","author":"T Pawe\u0142czyk","year":"2021","unstructured":"Pawe\u0142czyk T, Grancow-Grabka M, \u017burner N, Pawe\u0142czyk A. Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: findings from the OFFER randomized controlled study. Schizophr Res. 2021;230:61\u20138. https:\/\/doi.org\/10.1016\/j.schres.2021.02.012.","journal-title":"Schizophr Res"},{"key":"8091_CR74","doi-asserted-by":"publisher","first-page":"100262","DOI":"10.1016\/j.ejpsy.2024.100262","volume":"38","author":"A Sevillano-Jim\u00e9nez","year":"2024","unstructured":"Sevillano-Jim\u00e9nez A, Molina-Recio G, Garc\u00eda-Mellado JA, Molina-Luque R, Romero-Salda\u00f1a M. Psychopathological and cardiometabolic efficacy of a nutritional education intervention based on symbiotics in schizophrenia spectrum disorders. Two-arm randomised clinical trial. Eur J Psychiatry. 2024;38:100262. https:\/\/doi.org\/10.1016\/j.ejpsy.2024.100262.","journal-title":"Eur J Psychiatry"},{"key":"8091_CR75","doi-asserted-by":"publisher","first-page":"229","DOI":"10.32598\/CJNS.9.35.228.2","volume":"9","author":"R Soleimani","year":"2023","unstructured":"Soleimani R, Jalali MM, Bakhtiari H, Eslamdoust-Siahestalkhi F, Jalali SM. Probiotic add-on therapy in the first-episode schizophrenia: a randomized controlled trial. Casp J Neurol Sci. 2023;9:229\u201343. https:\/\/doi.org\/10.32598\/CJNS.9.35.228.2.","journal-title":"Casp J Neurol Sci"},{"key":"8091_CR76","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.3390\/nu11122950","volume":"11","author":"T Sori\u0107","year":"2019","unstructured":"Sori\u0107 T, Mavar M, Rumbak I. The effects of the dietary approaches to stop hypertension (DASH) diet on metabolic syndrome in hospitalized schizophrenic patients: a randomized controlled trial. Nutrients. 2019;11:2950. https:\/\/doi.org\/10.3390\/nu11122950.","journal-title":"Nutrients"},{"key":"8091_CR77","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jpsychires.2017.12.002","volume":"97","author":"N Sugawara","year":"2018","unstructured":"Sugawara N, Sagae T, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, et al. Effects of nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan: a randomized controlled trial. J Psychiatr Res. 2018;97:77\u201383. https:\/\/doi.org\/10.1016\/j.jpsychires.2017.12.002.","journal-title":"J Psychiatr Res"},{"key":"8091_CR78","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41398-022-01958-2","volume":"12","author":"J Huang","year":"2022","unstructured":"Huang J, Liu C, Yang Y, Kang D, Xiao J, Long Y, et al. The effects of probiotics plus dietary fiber on antipsychotic-induced weight gain: a randomized clinical trial. Transl Psychiatry. 2022;12:185. https:\/\/doi.org\/10.1038\/s41398-022-01958-2.","journal-title":"Transl Psychiatry"},{"key":"8091_CR79","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1590\/1516-4446-2014-1595","volume":"37","author":"E Andrade","year":"2015","unstructured":"Andrade E, Silva B, Cassilhas RC, Attux C, Cordeiro Q, Gadelha AL, Telles BA, et al. A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial. Rev Bras Psiquiatr. 2015;37:271\u20139. https:\/\/doi.org\/10.1590\/1516-4446-2014-1595.","journal-title":"Rev Bras Psiquiatr"},{"key":"8091_CR80","doi-asserted-by":"publisher","unstructured":"Battaglia G, Alesi M, Inguglia M, Roccella M, Caramazza G, Bellafiore M, et al. Soccer practice as an add-on treatment in the management of individuals with a diagnosis of schizophrenia. Neuropsychiatr Dis Treat. 2013;595\u2013604. https:\/\/doi.org\/10.2147\/NDT.S44066.","DOI":"10.2147\/NDT.S44066"},{"key":"8091_CR81","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1440-1819.2011.02225.x","volume":"65","author":"W Methapatara","year":"2011","unstructured":"Methapatara W, Srisurapanont M. Pedometer walking plus motivational interviewing program for Thai schizophrenic patients with obesity or overweight: a 12-week, randomized, controlled trial. Psychiatry Clin Neurosci. 2011;65:374\u201380. https:\/\/doi.org\/10.1111\/j.1440-1819.2011.02225.x.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"Suppl 1","key":"8091_CR82","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11606-016-3963-0","volume":"32","author":"AS Young","year":"2017","unstructured":"Young AS, Cohen AN, Goldberg R, Hellemann G, Kreyenbuhl J, Niv N, et al. Improving Weight in People with Serious Mental Illness: The Effectiveness of Computerized Services with Peer Coaches. J Gen Intern Med. 2017;32(Suppl 1):48\u201355. https:\/\/doi.org\/10.1007\/s11606-016-3963-0.","journal-title":"J Gen Intern Med"},{"key":"8091_CR83","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4088\/jcp.v66n0208","volume":"66","author":"JS Brar","year":"2005","unstructured":"Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiat. 2005;66:205\u201312. https:\/\/doi.org\/10.4088\/jcp.v66n0208.","journal-title":"J Clin Psychiat"},{"key":"8091_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22650","volume":"22","author":"RI Holt","year":"2018","unstructured":"Holt RI, Hind D, Gossage-Worrall R, Bradburn MJ, Saxon D, McCrone P, et al. Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technol Assess. 2018;22:1\u2013160. https:\/\/doi.org\/10.3310\/hta22650.","journal-title":"Health Technol Assess"},{"key":"8091_CR85","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.schres.2006.12.025","volume":"91","author":"Y Khazaal","year":"2007","unstructured":"Khazaal Y, Fresard E, Rabia S, Chatton A, Rothen S, Pomini V, et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res. 2007;91:169\u201377. https:\/\/doi.org\/10.1016\/j.schres.2006.12.025.","journal-title":"Schizophr Res"},{"key":"8091_CR86","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1547-5069.2003.00237.x","volume":"35","author":"KH Littrell","year":"2003","unstructured":"Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh: Off Publ Sigma Theta Tau Int Honor Soc Nurs. 2003;35:237\u201341. https:\/\/doi.org\/10.1111\/j.1547-5069.2003.00237.x.","journal-title":"J Nurs Scholarsh: Off Publ Sigma Theta Tau Int Honor Soc Nurs"},{"key":"8091_CR87","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2007-992148","volume":"41","author":"M Mauri","year":"2008","unstructured":"Mauri M, Simoncini M, Castrogiovanni S, Iovieno N, Cecconi D, Dell\u2019Agnello G, et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry. 2008;41:17\u201323. https:\/\/doi.org\/10.1055\/s-2007-992148.","journal-title":"Pharmacopsychiatry"},{"key":"8091_CR88","doi-asserted-by":"publisher","unstructured":"Mohanty K, Gandhi S, Muliyala KP, Thirthalli J, Binu VS, Sharma KK. Nurse counseling versus IEC material on maintenance of healthy lifestyle for outpatients receiving antipsychotics: a randomized controlled trial. Indian J Psychol Med. 2024;02537176241276152. https:\/\/doi.org\/10.1177\/02537176241276152.","DOI":"10.1177\/02537176241276152"},{"key":"8091_CR89","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1192\/bjo.2022.590","volume":"8","author":"B O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue B, Mifsud N, Castagnini E, Langstone A, Thompson A, Killackey E, et al. A single-blind, randomised controlled trial of a physical health nurse intervention to prevent weight gain and metabolic complications in first-episode psychosis: the physical health assistance in early psychosis (PHAstER) study. BJPsych Open. 2022;8:e189. https:\/\/doi.org\/10.1192\/bjo.2022.590.","journal-title":"BJPsych Open"},{"key":"8091_CR90","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1159\/000345975","volume":"5","author":"JC Ratliff","year":"2012","unstructured":"Ratliff JC, Palmese LB, Tonizzo KM, Chwastiak L, Tek C. Contingency management for the treatment of antipsychotic-induced weight gain: a randomized controlled pilot study. Obes Facts. 2012;5:919\u201327. https:\/\/doi.org\/10.1159\/000345975.","journal-title":"Obes Facts"},{"key":"8091_CR91","doi-asserted-by":"publisher","first-page":"104570","DOI":"10.1016\/j.ijnurstu.2023.104570","volume":"146","author":"S Meepring","year":"2023","unstructured":"Meepring S, Gray R, Li X, Chien WT, Li Y, Ho GWK, et al. Evaluating the efficacy of the thai health improvement profile intervention for preventing weight gain in people with early stage psychosis: a randomized controlled trial. Int J Nurs Stud. 2023;146:104570. https:\/\/doi.org\/10.1016\/j.ijnurstu.2023.104570.","journal-title":"Int J Nurs Stud"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08091-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:57:55Z","timestamp":1780441075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08091-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8091"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08091-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"437"}}